Search results
Results From The WOW.Com Content Network
A Trypanosomiasis vaccine is a vaccine against trypanosomiasis. No effective vaccine currently exists, but development of a vaccine is the subject of current research. The Bill & Melinda Gates Foundation has been involved in funding research conducted by the Sabin Vaccine Institute and others. [1] There are many obstacles to development of such ...
Serological testing is also common. One common way in which trypanosomiasis can be diagnosed in humans is through the detection of antibodies against trypanosomes made by host organisms. [6] One commonly used antibody test which operated based on this principle is the card agglutination test, C.A.T.T. for T. gambiense.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by Trypanosoma cruzi. It is spread mostly by insects in the subfamily Triatominae, known as "kissing bugs". The symptoms change throughout the infection.
Coronavirus diseases are caused by viruses in the coronavirus subfamily, a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, the group of viruses cause respiratory tract infections that can range from mild to lethal.
In California as of July 31, 37% of seniors had received the updated COVID-19 vaccine for the 2023–24 season, as did 18.7% of those age 50 to 64, and 10.1% of the youngest adults.
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine. [5] The company also partnered with Catalent , a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]